Anti-Mouse CD223 (LAG-3) – DyLight® 550

Pricing & Details

Product No.C2254
Clone
C9B7W
Protein
CD223
Formats AvailableView All
Product Type
Monoclonal Antibody
Isotype
Rat
IgG1
Applications
FC
Prod No.
Size
Price
Avail.
Qty
Add to cart
C2254-50 µg
50 µg
$85.00
In stock
Max:
Min: 1
Step: 1
C2254-100 µg
100 µg
$150.00
In stock
Max:
Min: 1
Step: 1
C2254-200 µg
200 µg
$250.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Mouse
Host Species
Rat
Immunogen
Purified Recombinant Mouse LAG-3
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 550 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 550 conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Excitation Laser
Yellow Laser (563 nm)
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone C9B7W recognizes and specifically binds to an epitope in the D2 domain of CD223.
Antigen Distribution
CD223 is expressed on T regulatory cells, activated T cells and NK cells.
Background
LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.

Antigen Details

Protein
PubMed
NCBI Gene Bank ID
Research Area
Immunology
.
Inhibitory Molecules
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.